GO:0040031 snRNA modification: Epitranscriptomic Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0040031 snRNA modification is the covalent alteration of nucleotides within small nuclear RNAs, changing their properties and function.
• The most studied snRNA modification is m6A on U6 snRNA, catalyzed by METTL16, which modulates pre-mRNA splicing.
• Pseudouridylation of U12 snRNA by scaRNA20 is required for cardiomyogenesis, linking snRNA modification to cardiac differentiation.
• Spliceosomal snRNA epitranscriptomics is an emerging field connecting RNA modifications to splicing fidelity and disease.
• NSUN5/TET2-mediated 5-methylcytosine to 5-hydroxymethylcytosine conversion on chromatin-associated RNA governs glioma immune evasion.
• Mutations in snRNA genes and their modification machinery are increasingly recognized in Mendelian disorders.
Description
Small nuclear RNAs (snRNAs) are essential components of the spliceosome, the ribonucleoprotein machine that removes introns from pre-mRNA. Beyond their canonical roles, snRNAs undergo covalent nucleotide modifications that alter their structure, stability, and interactions with proteins and other RNAs. The Gene Ontology term GO:0040031, snRNA modification, captures this biological process: the covalent alteration of one or more nucleotides within snRNA, resulting in a change in the properties of the snRNA. Understanding snRNA modification is critical because these chemical marks directly influence splice site selection, splicing efficiency, and the fidelity of gene expression. Recent structural and mechanistic studies have revealed how enzymes such as METTL16 recognize and methylate U6 snRNA, providing a molecular framework for this process. Moreover, dysregulation of snRNA modification has been linked to cancer, cardiovascular defects, and Mendelian disorders, making it a high-priority area for both basic and translational research.
snRNA modification At A Glance
| GO ID | GO:0040031 |
|---|---|
| GO term | snRNA modification |
| Ontology | biological_process |
| Synonym | none |
| Major function | Covalent alteration of snRNA nucleotides, modulating spliceosome assembly and pre-mRNA splicing |
| Key enzymes | METTL16 (m6A on U6 snRNA), pseudouridine synthases (e.g., scaRNA20-guided), NSUN5/TET2 |
| Substrates | U6 snRNA, U12 snRNA, other spliceosomal snRNAs |
| Associated processes | Pre-mRNA splicing, splice site selection, cardiomyogenesis, immune evasion |
What Is GO:0040031?
GO:0040031 snRNA modification is defined as the covalent alteration of one or more nucleotides within a small nuclear RNA (snRNA), resulting in a change in the properties of that snRNA. This includes enzymatic addition of methyl groups (e.g., m6A), pseudouridylation, and other chemical changes that affect snRNA folding, stability, or interactions. The process is distinct from transcription or processing of snRNA; it is a post-transcriptional epitranscriptomic event that fine-tunes spliceosomal function.
Why Is snRNA modification Important in Cell Biology?
snRNA modifications are not decorative; they are functional switches that tune the spliceosome. For example, m6A on U6 snRNA is required for accurate and efficient splicing of pre-mRNAs in both C. elegans and humans. This modification influences the usage of two major classes of pre-mRNA 5' splice sites, thereby shaping transcript diversity. Beyond splicing, pseudouridylation of U12 snRNA promotes cardiomyogenesis, revealing a role in cell fate decisions. The clinical relevance is underscored by the emerging link between snRNA gene mutations and Mendelian disorders, as well as the involvement of RNA modification enzymes in cancer immune evasion. Thus, studying GO:0040031 provides mechanistic insight into gene regulation and identifies potential therapeutic targets.
• Controls splice site selection and splicing fidelity, directly affecting proteome diversity.
• Required for normal development, including cardiomyogenesis via U12 snRNA pseudouridylation.
• Implicated in Mendelian disorders caused by mutations in snRNA genes or modification machinery.
• Modulates immune evasion in glioma through NSUN5/TET2-mediated RNA modification.
• Provides a paradigm for epitranscriptomic regulation of non-coding RNAs.
• Offers targets for therapeutic intervention in splicing-related diseases.
• Enables researchers to study RNA-protein interactions and enzyme specificity.
• Connects RNA modification to chromatin-associated RNA and 5hmC dynamics.
What Happens During snRNA modification?
Recognition and Binding of snRNA by Modification Enzymes
In simple terms: First, the enzyme finds and grabs the snRNA at a specific spot.
Modification enzymes such as METTL16 recognize specific sequence and structural features within snRNA. Structural studies of human METTL16 bound to U6 snRNA reveal how the enzyme engages the RNA to position the target adenosine for methylation. Mechanistic insights show that METTL16 uses a base-flipping mechanism to access the target nucleotide, ensuring modification specificity. This step is critical for downstream chemical alteration.
Catalytic Transfer of the Modifying Group
In simple terms: The enzyme then attaches a chemical tag, like a methyl group, onto the RNA letter.
For m6A modification, METTL16 transfers a methyl group from S-adenosylmethionine to the N6 position of adenosine within U6 snRNA. This covalent alteration changes the chemical properties of the snRNA, influencing its local structure and interactions. The reaction is highly specific and regulated to occur only on particular snRNA substrates.
Pseudouridylation of snRNA
In simple terms: Another type of modification converts a uridine letter into a pseudouridine, which changes how the RNA folds.
Pseudouridylation is a common snRNA modification. scaRNA20 guides the pseudouridylatory modification of U12 snRNA, and this modification improves cardiomyogenesis. This isomerization reaction is catalyzed by pseudouridine synthases and can alter RNA structure and stability, impacting spliceosomal function.
Functional Consequences for Splicing
In simple terms: After modification, the snRNA works better or differently in the splicing machine.
m6A modification of U6 snRNA modulates usage of two major classes of pre-mRNA 5' splice sites, thereby affecting splicing outcomes. Furthermore, U6 snRNA m6A modification is required for accurate and efficient splicing of C. elegans and human pre-mRNAs. These functional consequences demonstrate how a single chemical mark on snRNA can have widespread effects on gene expression.
Regulation and Dynamics of snRNA Modification
In simple terms: The cell can add or remove these tags to control splicing when needed.
The levels and patterns of snRNA modifications are dynamically regulated. Spliceosomal snRNA epitranscriptomics is an emerging area that studies how these modifications are written, erased, and read. For instance, NSUN5/TET2-directed conversion of 5-methylcytosine to 5-hydroxymethylcytosine on chromatin-associated RNA governs glioma immune evasion, indicating crosstalk between RNA modification pathways.
Key Genes Involved in GO:0040031 snRNA modification
The following genes and proteins are central to snRNA modification, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL16 | m6A methyltransferase that modifies U6 snRNA | Structural and mechanistic studies of U6 m6A modification |
| U6 snRNA | Spliceosomal RNA substrate for m6A modification | Modulates 5' splice site usage and splicing efficiency |
| U12 snRNA | Minor spliceosomal RNA substrate for pseudouridylation | Pseudouridylation by scaRNA20 promotes cardiomyogenesis |
| scaRNA20 | Small Cajal body-specific RNA that guides U12 pseudouridylation | Improves cardiomyogenesis via U12 modification |
| NSUN5 | RNA methyltransferase involved in 5mC modification | Chromatin-associated RNA modification and glioma immune evasion |
| TET2 | Ten-eleven translocation enzyme that converts 5mC to 5hmC | Governs glioma immune evasion via RNA modification |
| Spliceosomal snRNAs | Core components of the spliceosome | Epitranscriptomic regulation of splicing |
| Pseudouridine synthases | Enzymes that catalyze pseudouridylation | snRNA modification and structural effects |
| m6A readers | Proteins that recognize m6A marks | Interpretation of snRNA modifications |
| m6A erasers | Proteins that remove m6A marks | Dynamic regulation of snRNA modification |
| SMN complex | Assembles snRNPs | snRNA modification impacts snRNP assembly |
| Cajal body components | Site of snRNA modification and snRNP assembly | scaRNA-guided modification |
| Pre-mRNA splicing factors | Interact with modified snRNAs | Splice site selection |
| Mendelian disorder genes | snRNA genes mutated in human disorders | Link to Mendelian disorders |
How Is snRNA modification Regulated?
snRNA modification is regulated at multiple levels. The expression and activity of modification enzymes such as METTL16 are subject to cellular control, and the modification status of snRNAs can change in response to developmental or environmental cues. For example, scaRNA20-guided pseudouridylation of U12 snRNA is important for cardiomyogenesis, suggesting developmental regulation. Additionally, crosstalk between different RNA modifications, such as NSUN5/TET2-mediated 5mC to 5hmC conversion, indicates that snRNA modification is integrated into broader epitranscriptomic networks. However, specific upstream signaling pathways (e.g., mTOR, ISR) that regulate snRNA modification enzymes are not well-defined in the provided literature and require further investigation.
snRNA modification and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL16 | Splicing dysregulation, potential cancer | Knockout and point-mutation cell lines |
| U6 snRNA | Splicing-related disorders | Knock-in of modified or unmodified U6 variants |
| scaRNA20 | Cardiovascular development | Overexpression and knockout in cardiomyocyte models |
| NSUN5/TET2 | Glioma immune evasion | Knockout and overexpression in glioma cells |
| snRNA genes | Mendelian disorders | Patient-derived cells and CRISPR models |
snRNA Modification in Cancer
Dysregulation of RNA modification enzymes contributes to cancer progression. NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion, highlighting a role for RNA modifications in tumor immunity. Although this study focuses on chromatin-associated RNA, it underscores the broader importance of RNA modification pathways in cancer. Given that snRNA modifications influence splicing, altered snRNA modification could contribute to oncogenic splicing patterns, though direct evidence in the provided literature is limited.
snRNA Modification in Cardiovascular Development
Pseudouridylation of U12 snRNA by scaRNA20 improves cardiomyogenesis, linking snRNA modification to cardiac differentiation. This suggests that defects in snRNA modification could contribute to congenital heart defects or impaired cardiac regeneration. The study provides a mechanistic basis for exploring snRNA modification as a therapeutic target in cardiovascular disease.
snRNA Genes and Mendelian Disorders
Small nuclear RNA genes are increasingly recognized in Mendelian disorders. Mutations in snRNA genes or in the machinery that modifies them can disrupt splicing and cause disease. This review highlights the clinical relevance of snRNA biology and motivates further research into how specific modifications contribute to disease phenotypes.
From snRNA modification-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does METTL16-mediated m6A on U6 snRNA control splice site choice? | METTL16 knockout and point-mutation cell lines |
| Is U12 snRNA pseudouridylation required for cardiomyogenesis? | scaRNA20 knockout and overexpression in cardiomyocytes |
| How does NSUN5/TET2-mediated RNA modification affect immune evasion? | NSUN5/TET2 knockout and overexpression in glioma cells |
| What are the structural determinants of METTL16 specificity? | Recombinant METTL16 with U6 snRNA variants |
| Do snRNA gene mutations cause Mendelian disorders? | Patient-derived iPSCs and CRISPR knock-in |
| Can snRNA modification be dynamically regulated? | Inducible overexpression and knockout of modification enzymes |
How to Study the snRNA modification Process
| Method | What It Measures | Typical Application |
|---|---|---|
| m6A-seq / MeRIP-seq | Global m6A modification sites | Mapping U6 snRNA m6A |
| Pseudouridine-seq | Pseudouridine sites | Detecting U12 snRNA pseudouridylation |
| In vitro methylation assay | Enzymatic activity of METTL16 | Mechanistic studies |
| Minigene splicing reporter | Splice site usage | Functional impact of snRNA modification |
| CRISPR knockout | Gene function loss | Testing METTL16, scaRNA20 roles |
| CRISPR knock-in | Specific mutations or tags | Modeling patient variants |
| RNA immunoprecipitation | RNA-protein interactions | Identifying modification enzyme targets |
| Structural biology (cryo-EM) | 3D structure of enzyme-RNA complexes | Understanding METTL16-U6 snRNA binding |
RNA Sequencing and Modification Mapping
RNA-seq and specialized modification mapping techniques (e.g., m6A-seq, pseudouridine-seq) allow global profiling of snRNA modifications. These methods can identify which snRNAs are modified and how modifications change under different conditions. For m6A on U6 snRNA, targeted approaches such as m6A-IP followed by qPCR can quantify specific marks.
Structural Biology and Biochemistry
Structural studies using X-ray crystallography or cryo-EM reveal how enzymes like METTL16 recognize and modify snRNA. In vitro methylation assays with recombinant enzymes and synthetic snRNA substrates provide mechanistic insights into catalytic activity and specificity.
Functional Splicing Assays
Minigene splicing reporters and transcriptome-wide splicing analysis (e.g., RNA-seq) can assess the impact of snRNA modifications on splice site selection and splicing efficiency. These assays are essential to link modification status to functional outcomes.
CRISPR-Based Perturbation
CRISPR knockout, knock-in, and point-mutation models enable causal testing of genes involved in snRNA modification. For example, knocking out METTL16 or mutating its catalytic domain can reveal its role in U6 snRNA methylation and splicing. Similarly, knockout of scaRNA20 can test its requirement for U12 pseudouridylation and cardiomyogenesis.
How CRISPR Can Be Used to Study GO:0040031 snRNA modification
Knockout
CRISPR knockout of genes encoding snRNA modification enzymes, such as METTL16, allows researchers to assess loss-of-function phenotypes. For example, METTL16 knockout reduces U6 snRNA m6A levels and alters splicing patterns. Knockout of scaRNA20 can test its role in U12 snRNA pseudouridylation and cardiomyogenesis.
Point Mutation
Introducing point mutations in catalytic residues of METTL16 or in the target adenosine of U6 snRNA can dissect the importance of specific modifications. Such models help distinguish between catalytic activity and structural roles.
Knock-in
Knock-in of tagged versions of modification enzymes or of mutant snRNA genes enables tracking and functional studies. For instance, knocking in a tagged METTL16 allows immunoprecipitation and localization studies. Knock-in of patient-derived snRNA mutations can model Mendelian disorders.
Overexpression
Overexpression of modification enzymes or guide RNAs (e.g., scaRNA20) can enhance specific modifications and test sufficiency. Overexpression of scaRNA20 improves cardiomyogenesis, demonstrating a gain-of-function approach. Overexpression of NSUN5/TET2 can modulate immune evasion in glioma models.
How EDITGENE Supports snRNA modification Research
Researchers studying snRNA modification-related genes often need to determine whether a candidate gene is causally involved in the modification process, splicing regulation, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for snRNA modification research.
Frequently Asked Questions About snRNA modification
What is snRNA modification?
snRNA modification is the covalent alteration of nucleotides within small nuclear RNAs, changing their properties and affecting spliceosome function.
What genes are involved in snRNA modification?
Key genes include METTL16, which methylates U6 snRNA, and scaRNA20, which guides U12 snRNA pseudouridylation, among others.
What is the role of METTL16 in snRNA modification?
METTL16 is an m6A methyltransferase that modifies U6 snRNA, influencing pre-mRNA splicing and splice site selection.
How does m6A modification of U6 snRNA affect splicing?
m6A on U6 snRNA modulates the usage of two major classes of pre-mRNA 5' splice sites and is required for accurate and efficient splicing.
What is pseudouridylation of snRNA?
Pseudouridylation is the conversion of uridine to pseudouridine within snRNA, which can alter RNA structure and function; scaRNA20 guides this modification on U12 snRNA.
Is snRNA modification linked to human disease?
Yes, mutations in snRNA genes are associated with Mendelian disorders, and dysregulation of RNA modification enzymes contributes to cancer and cardiovascular defects.
How can I study snRNA modification in the lab?
Common methods include m6A-seq, pseudouridine-seq, in vitro methylation assays, and CRISPR knockout of modification enzymes.
What are the main types of snRNA modifications?
The most studied are m6A methylation and pseudouridylation, but other modifications such as 5-methylcytosine and its derivatives also occur.
Which snRNAs are modified?
U6 snRNA is modified by METTL16, and U12 snRNA is pseudouridylated by scaRNA20; other spliceosomal snRNAs are also subject to modification.
Can CRISPR be used to study snRNA modification?
Yes, CRISPR knockout, knock-in, and point mutation models enable causal testing of genes involved in snRNA modification and their downstream effects.
Conclusion
GO:0040031 snRNA modification is a fundamental epitranscriptomic process that fine-tunes spliceosomal function and gene expression. Key enzymes such as METTL16 and guide RNAs like scaRNA20 introduce chemical marks that influence splicing fidelity, cell differentiation, and disease. Understanding these modifications offers insights into basic RNA biology and potential therapeutic avenues. EDITGENE provides the CRISPR tools and services needed to dissect this process and accelerate discovery.
References
- 1. Ju J et al.. 2025. Structures and mechanisms of U6 snRNA m(6)A modification by METTL16.. Nat Commun 16(1):7708 PMID: 40841561
- 2. Aoyama T et al.. 2020. Mechanistic insights into m6A modification of U6 snRNA by human METTL16.. Nucleic Acids Res 48(9):5157-5168 PMID: 32266935
- 3. Perales S et al.. 2024. scaRNA20 promotes pseudouridylatory modification of small nuclear snRNA U12 and improves cardiomyogenesis.. Exp Cell Res 436(1):113961 PMID: 38341080
- 4. Morais P et al.. 2021. Spliceosomal snRNA Epitranscriptomics.. Front Genet 12:652129 PMID: 33737950
- 5. Antonarakis SE. 2026. Small nuclear RNA genes in Mendelian disorders.. Nat Genet 58(1):28-38 PMID: 41345251
- 6. Wu R et al.. 2024. NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion.. Proc Natl Acad Sci U S A 121(14):e2321611121 PMID: 38547058
- 7. Parker MT et al.. 2022. m(6)A modification of U6 snRNA modulates usage of two major classes of pre-mRNA 5' splice site.. Elife 11 PMID: 36409063
- 8. Shen A et al.. 2024. U6 snRNA m6A modification is required for accurate and efficient splicing of C. elegans and human pre-mRNAs.. Nucleic Acids Res 52(15):9139-9160 PMID: 38808663
